Michael Keller

Has grant

Assistant Professor

George Washington University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Keller is an Assistant Professor at George Washington University in the United States. His research focuses on cellular therapies, particularly in the context of gene therapy, T-cell treatment for viral infections, and safety surveillance in clinical trials. Recent publications highlight his work on enzyme replacement therapy for ADA-SCID and T-cell therapies targeting HIV and other viral reactivations following solid organ transplants.

Recent Grants

Grant: Close

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES)

Open Date: 2018-06-01

Close Date: 2022-06-01

Grant: Close

Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency Disorders

Open Date: 2017-04-01

Close Date: 2020-03-31

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

UNITED STATES

View details

Patrick Hanley

Associate Professor

George Washington University

UNITED STATES

View details

Michael S. Grimley

University of Cincinnati College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Keller

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (9)

Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy

Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant

Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment

Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.

Virus-specific T-cell therapies for patients with primary immune deficiency

Collaborators (7)

Paibel Aguayo-HIraldo

Christopher Lazarski

Thomas Galletta

Satiro De Oliveira

Shanmuganathan Chandrakasan

Patrick Hanley

Michael S. Grimley

Make your next move.